HSBC Holdings’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

HSBC Holdings’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$40.8M	Buy	320,100 +19,100	+6%	+$2.38M	0.02%	559
2025 Q4	$36.9M	Buy	+301,000	New	+$34.5M	0.02%	575
2025 Q3	–	Sell	-44,600	Closed	-$3.7M	–	3195
2025 Q2	$3.7M	Buy	+44,600	New	+$3.56M	﹤0.01%	1260
2025 Q1	–	Sell	-294,600	Closed	-$26.5M	–	3304
2024 Q4	$26.5M	Buy	+294,600	New	+$28.5M	0.02%	662
2019 Q4	–	Sell	-27,000	Closed	-$2.06M	–	3206
2019 Q3	$2.06M	Buy	+27,000	New	+$2.24M	﹤0.01%	1581
2019 Q1	–	Sell	-31,000	Closed	-$2.22M	–	2908
2018 Q4	$2.22M	Buy	+31,000	New	+$2.5M	﹤0.01%	1461

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

HSBC Holdings's XBI Position: Q1 2026 in Review

HSBC Holdings increased its State Street SPDR S&P Biotech ETF (XBI) stake by 14% in Q1 2026, buying an estimated $10.9M and bringing the position to 725,538 shares worth $92.6M. The position accounts for 0.05% of the portfolio, ranked #355.

HSBC Holdings first reported a position in XBI in Q2 2013 and has held it in 51 quarters since. The position peaked at $103M in Q4 2023. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

HSBC Holdings held 725,538 shares of State Street SPDR S&P Biotech ETF worth $92.6M as of Q1 2026.
HSBC Holdings bought 87,009 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $10.9M.
State Street SPDR S&P Biotech ETF made up 0.05% of HSBC Holdings's portfolio in Q1 2026, its #355 holding.
HSBC Holdings first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 51 quarters since.
HSBC Holdings's State Street SPDR S&P Biotech ETF position peaked at $103M in Q4 2023.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.